• NOVEMBER 20, 2001

Dr. Reddy’s: Lessons from Omeprazole

Yesterday, Dr. Reddy’s ADR was down by around 18% on the NYSE following withdrawal of tentative Omeprazole approval which seems to have worked as a major anti-climax for investors. Whether the fall was justified or the market overreacted to the news is a different story but the point here is investors need to understand the nature of generic business before investing.

Apart from the company’s capability, what matters is the timing, patience, skills and financial muscle to fight legal battles. This is all the more true in case of Para IV applications. A Para IV application is one in which a generic company challenges a patented product to prove that the generic version can stand the same test of efficacy. Further, to get six months marketing exclusivity the company also needs to be the first to file this application.

Now, the cream for the original innovator of the drug is the period the drug remains under patent, as it charges a hefty premium for it innovation and monopoly. Off course, the innovator would try to prevent the entry of a generic product and to do so various legal provisions; loopholes and financial muscle are used as war tactics. It is after all this legal drama that the generic drug enters a regulated market. Now, one can understand the degree of uncertainty, which precedes and follows launch of a generic product.

Let us consider a recent Bristol Myers, BuSpar case to understand the complexities. BuSpar is Bristol Myers multi-million anti-anxiety drug. After its patent expiry, a lower court in the US gave the green signal for entry of two generic copycats (from Watson and Mylan). However, months after the lower court gave this decision, US Court of Appeals reversed the earlier decision stating the lower court had no power to order US FDA to overlook the patent and pave the way for generics.

To conclude, there is a big opportunity waiting for Indian generic companies who are geared to latch on to that market. However, the road ahead would not be smooth and there would be negative surprises along the way. It would be advisable for investors in domestic pharma companies not to build expectations and factor in growth numbers either from generics or from R&D potential till clear earnings visibility arises on that front.

  • Read on the latest Omeprazole development

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited (Research Analyst)
    103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407